Project Grant R43CA298055
Award Date
1/1/25
Completion Date
6/30/25
Dollars Obligated
$301K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Durham, NC 27707, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $400,000 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Electronic Biosciences, Inc. The goal of this 1-year project is to develop a novel nanopore-based sequencing technology that can accurately and precisely sequence repetitive DNA sequences, which are known to have significant variations correlated with cancer progression but have been challenging to characterize using current sequencing methods. The...
This federal Project Grant award from the National Human Genome Research Institute (NHGRI), under the Human Genome Research (CFDA 93.172) program, provides $215,088.00 to Directseq Biosciences, Inc. to develop an "exhaustive de novo RNA sequencing method" using next-generation mass spectrometry. The goal is to create a comprehensive approach that can directly identify and sequence every RNA species in a sample, as well as fully profile all RNA modifications, without bias or...
The National Cancer Institute (NCI) awarded a $554,653 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Institute for Systems Biology in Seattle, Washington. The grant, titled "RARECYTEFINDER: A BENCH-TO-BITS TOOLKIT FOR LABEL-FREE, WHOLE-SPECTRUM ANALYSIS OF RARE DISSEMINATED TUMOR CELLS IN LIQUID AND TISSUE BIOPSIES", seeks to develop an innovative, unbiased method for identifying and analyzing rare disseminated tumor cells (DTCs) in liquid and tissue...
This $440,287 Project Grant awarded by the National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research) aims to establish a simplified and accessible procedure for simultaneous extraction of DNA, RNA, and protein from tumor touch imprints. This research will leverage tumor touch imprints on glass slides as a biobanking method, in combination with a multi-analyte molecular extraction protocol previously developed for forensic applications. The key products or services to be...
This federal Project Grant award for $350,000 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports the development of a neural network-accelerated DNA and RNA sequence processing node, called CLEDGESEQ, for use in edge computing applications.
The primary objectives are to: 1) Develop neural network-based Next Generation Sequencing (NGS) data processing routines for mapping, assembly, and analysis on edge...
The federal Project Grant award, provided by the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to develop and evaluate a non-invasive assay to detect and monitor the level of circulating free DNA (cfDNA) from tumor cells in saliva samples. The $295,757 award to Nord Bio Inc., with a project period from July 2024 to June 2025, will investigate the use of saliva-derived cfDNA for cancer detection and minimal residual disease monitoring,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $399,970 to Duo Oncology Inc. to develop DUO-207, an innovative nanomedicine to improve treatment for pancreatic cancer. DUO-207 is a fixed-dose combination of a polymer-conjugated gemcitabine and paclitaxel that aims to overcome the delivery challenges of existing nanomedicines for pancreatic cancer. The award supports preclinical studies to evaluate the safety...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a novel circulating tumor DNA (ctDNA) assay technology by Binary Genomics, Inc. to monitor the efficacy of immunotherapy treatments for non-small cell lung cancer. The $398,040 award over 18 months will enable the company to evaluate the analytical and baseline clinical performance of their ctDNA assay, which aims to address limitations of existing...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $455,000 to Atlas Biologics, LLC to develop and commercialize a novel "Deep Mutational Scanning with Duplex Sequencing" (DMS-DS) platform for evaluating the mutational landscape of anti-cancer drug targets.
The objective is to refine and scale the DMS-DS technology into an industry-viable screening platform that can accurately predict the mutational resistance...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $999,554 to Orbit Genomics, Inc. to develop a high-sensitivity, high-specificity lung cancer subtyping diagnostic test. The goal is to create a test that can accurately distinguish different lung cancer subtypes, enabling more effective treatment selection and improved patient outcomes. The award will fund the collection of clinical samples, enhancement of Orbit...